Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 5/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1,4-Butanediol SCHEMBL924160 | 0.97 | CA2 (0.37) | GPR84FFAR1FFAR4LMNATSHR | |
| 1,3-Propanediol SCHEMBL920408 | 0.91 | CA2 (0.37) | TSHRCA2TDP1 | |
| Ethylene Glycol SCHEMBL921115 | 0.84 | CA2 (0.41) | TSHRCA2TDP1 | |
| Ethylene Glycol SCHEMBL7202667 | 0.84 | CA2 (0.41) | TSHRCA2TDP1 | |
| 1,5-Pentanediol SCHEMBL923627 | 0.81 | CA5A (0.46) | GPR84FFAR1FFAR4LMNATSHR | |
| 1,6-Hexanediol SCHEMBL28157698 | 0.81 | CA5A (0.46) | GPR84FFAR1FFAR4LMNATSHR | |
| 1,5-Pentanediol SCHEMBL1896067 | 0.81 | CA5A (0.46) | GPR84FFAR1FFAR4LMNATSHR | |
| SCHEMBL923629 | 0.79 | CA1 (0.38) | LMNATSHRALDH1A1CA2CA12 | |
| 1,4-Butanediol SCHEMBL924158 | 0.77 | CA5A (0.50) | GPR84FFAR1FFAR4LMNATSHR | |
| 1,4-Butanediol SCHEMBL445780 | 0.77 | CA5A (0.50) | GPR84FFAR1FFAR4LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110002875-A1 | METHOD FOR TREATING AMYLOIDOSIS | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2011-01-06 | — | — | US | claimed |
| EP-1064013-A4 | $i(IN VITRO) FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | UNIV WASHINGTON (US) | 2005-05-11 | — | — | EP | claimed |
| US-20030108595-A1 | Method for treating amyloidosis | QUEEN'S UNIVERSITY AT KINGSTON | 2003-06-12 | — | — | US | claimed |
| US-20010048941-A1 | Method for treating amyloidosis | QUEEN'S UNIVERSITY OF KINGSTON | 2001-12-06 | — | — | US | claimed |
| EP-1064013-A1 | $i(IN VITRO) FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | University of Washington (US) | 2001-01-03 | — | — | EP | claimed |
| WO-1999045947-A9 | IN VITRO FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | UNIV WASHINGTON (US) | 2000-03-02 | — | — | WO | claimed |
| WO-1999045947-A1 | IN VITRO FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | UNIVERSITY OF WASHINGTON (US) | 1999-09-16 | — | — | WO | claimed |
| US-5643562-A | ANTIDEPOSIT AGENTS FOR PROTEINS FOR MEDICAL DIAGNOSIS OF DISEASES | QUEEN'S UNIVERSITY OF KINGSTON (CA) | 1997-07-01 | — | — | US | claimed |
| US-20110002875-A1 | METHOD FOR TREATING AMYLOIDOSIS | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2011-01-06 | — | — | US | disclosed |
| US-7754761-B2 | Sulfonated compounds and compositions for treating amyloidosis | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2010-07-13 | — | — | US | disclosed |
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20080249184-A1 | Methods for modulating neuronal cell death | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2008-10-09 | — | — | US | disclosed |
| US-20070265334-A1 | Method for treating amyloidosis | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-11-15 | — | — | US | disclosed |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
| WO-1999040909-A1 | METHOD FOR MODULATING MACROPHAGE ACTIVATION | NEUROCHEM, INC. (CA) | 1999-08-19 | — | — | WO | disclosed |
| US-5840294-A | INHIBITING AMYLOID DEPOSITION BY ADMINISTERING A THERAPEUTIC COMPOUND COMPRISING AN ANIONIC GROUP AND A CARRIER MOLECULE | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1998-11-24 | — | — | US | disclosed |
| US-5728375-A | ADMINISTERING A COMPOUND COMPRISING AN ANIONIC GROUP AND A CARRIER MOLECULE; INHIBITS DEPOSITION BY PREVENTING INTERACTION BETWEEN AN AMYLOIDOGENIC PROTEIN AND A BASEMENT MEMBRANE CONSTITUENT | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1998-03-17 | — | — | US | disclosed |
| EP-0814842-A1 | METHOD FOR TREATING AMYLOIDOSIS | Queen's University at Kingston (CA) | 1998-01-07 | — | — | EP | disclosed |
| US-5643562-A | ANTIDEPOSIT AGENTS FOR PROTEINS FOR MEDICAL DIAGNOSIS OF DISEASES | QUEEN'S UNIVERSITY OF KINGSTON (CA) | 1997-07-01 | — | — | US | disclosed |
| WO-1996028187-A1 | METHOD FOR TREATING AMYLOIDOSIS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1996-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265334-A1 | Method for treating amyloidosis | TTR, IAPP, APP | GPR84 3546/4885FFAR1 3385/4885FFAR4 3387/4885 |
| US-20030108595-A1 | Method for treating amyloidosis | TTR, IAPP, APP | GPR84 3546/4885FFAR1 3385/4885FFAR4 3387/4885 |
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | APP, PYGB, MAPT | GPR84 1660/4885FFAR1 3370/4885FFAR4 3657/4885 |
| US-20080249184-A1 | Methods for modulating neuronal cell death | GAP43, BAD, NLN | GPR84 1427/4885FFAR1 1745/4885FFAR4 2743/4885 |
| US-20010048941-A1 | Method for treating amyloidosis | TTR, APOB, NEFM | GPR84 3432/4885FFAR1 3479/4885FFAR4 3036/4885 |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CD44, CSGALNACT1 | GPR84 3776/4885FFAR1 3953/4885FFAR4 3850/4885 |
| US-20110002875-A1 | METHOD FOR TREATING AMYLOIDOSIS | TTR, IAPP, APP | GPR84 3546/4885FFAR1 3385/4885FFAR4 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.